Anavex2-73 Shows Efficacy in Fragile X Mouse Study, Phase 2/3 Trial Planned

Anavex2-73 Shows Efficacy in Fragile X Mouse Study, Phase 2/3 Trial Planned

305006

Anavex2-73 Shows Efficacy in Fragile X Mouse Study, Phase 2/3 Trial Planned

Treatment with Anavex2-73 (blarcamesine) safely and significantly eased behavioral symptoms of fragile X syndrome (FXS), and normalized some aspects of brain chemistry, in a preclinical study in mice. Anavex Life Sciences, the company developing this treatment candidate, is now looking to begin clinical testing of the medication in fragile X patients. Results were  in the study “Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy,”…

You must be logged in to read/download the full post.